MedPath

Sun Pharmaceutical Industries, Inc.

🇺🇸United States
Ownership
Subsidiary
Employees
-
Market Cap
-
Website
http://sunpharma.com/usa

Clinical Trials

4

Active:3
Completed:1

Trial Phases

2 Phases

Phase 1:3
Phase 3:1

Drug Approvals

240

FDA:238
CANADA:1

Drug Approvals

Hydrocortisone

Approval Date
May 27, 2025
FDA

Miconazole Nitrate

Approval Date
May 27, 2025
FDA

Deferiprone

Approval Date
May 19, 2025
FDA

Clotrimazole

Approval Date
Apr 23, 2025
FDA

tramadol hydrochloride

Approval Date
Mar 28, 2024
FDA

Methylphenidate Hydrochloride

Approval Date
Mar 27, 2024
FDA

Carvedilol Phosphate

Approval Date
Mar 6, 2024
FDA

Bosentan

Approval Date
Mar 5, 2024
FDA

sumatriptan succinate

Approval Date
Feb 29, 2024
FDA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 24
  • Next

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Phase 1
3 (75.0%)
Phase 3
1 (25.0%)

European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

Phase 3
Completed
Conditions
Alopecia Areata
Interventions
First Posted Date
2021-09-13
Last Posted Date
2025-06-17
Lead Sponsor
Sun Pharmaceutical Industries, Inc.
Target Recruit Count
407
Registration Number
NCT05041803
Locations
🇫🇷

Service de Dermatologie CHRU de Brest - Hopital Morvan, Brest Cedex, Finistere, France

🇫🇷

Service de Dermatologie Centre Hospitalier Universitaire de Nice - Hopital Archet 2, Nice, Provence-Alpes-Cote d'Azur, France

🇫🇷

CHU de Bordeaux, Hopital Saint-Andre, Bordeaux, France

and more 36 locations

News

Sun Pharma Discontinues Psoriasis and Eczema Drug SCD-044 After Phase 2 Trial Failures

Sun Pharma's experimental oral drug SCD-044 (Vibozilimod) failed to meet primary endpoints in Phase 2 trials for both psoriasis and atopic dermatitis, missing the 75% improvement target in PASI and EASI scores at 16 weeks.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.